Click Therapeutics -Model CT-132 -Migraine
CT-132 is under development as a clinically-validated digital program for migraine.
Most popular related searches
- Confidential
CT-132 combines multiple clinically-validated mechanisms of action with Click’s adaptive patient engagement platform and is designed to reduce the number of migraines per month in patients with four or more migraine days per month. Click is seeking FDA clearance for CT-132 as a Class II medical device for the preventive treatment of migraine in adults.